Confidence in Arbutus Biopharma (ABUS) Shares by Wedbush Fall.

March 19, 2018 - By Michael Collier

 Confidence in Arbutus Biopharma (ABUS) Shares by Wedbush Fall.

Arbutus Biopharma (ABUS) Receives a Downgrade

Wedbush has given Arbutus Biopharma (ABUS) shares a new “Neutral” rating in a research note sent to clients and investors on Monday, 19 March. This was a cut from the old “Outperform” rating.

Arbutus Biopharma Corporation (NASDAQ:ABUS) Ratings Coverage

Among 3 analysts covering Arbutus Biopharma Corporation (ABUS), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Arbutus Biopharma Corporation has $10.0 highest and $10 lowest target. $10’s average target is 94.17% above currents $5.15 stock price. Arbutus Biopharma Corporation had 4 analyst reports since January 4, 2018 according to SRatingsIntel. The stock of Arbutus Biopharma Corporation (NASDAQ:ABUS) earned “Neutral” rating by Wedbush on Monday, March 19. The firm has “Buy” rating by FBR Capital given on Thursday, March 15.

The stock decreased 1.90% or $0.1 during the last trading session, reaching $5.15. About 69,892 shares traded. Arbutus Biopharma Corporation (ABUS) has declined 2.31% since March 19, 2017 and is downtrending. It has underperformed by 19.01% the S&P500.

Analysts await Arbutus Biopharma Corporation (NASDAQ:ABUS) to report earnings on March, 20. They expect $-0.39 earnings per share, down 2.63 % or $0.01 from last year’s $-0.38 per share. After $-0.17 actual earnings per share reported by Arbutus Biopharma Corporation for the previous quarter, Wall Street now forecasts 129.41 % negative EPS growth.

Arbutus Biopharma Corporation, a biopharmaceutical company, engages in discovering, developing, and commercializing a cure for patients suffering from chronic Hepatitis B virus infection in Canada and the United States. The company has market cap of $283.61 million. It also develops a pipeline of products based on RNA interference therapeutics (RNAi). It currently has negative earnings. The company??s lead candidate is ARB-1467, which is in a Phase II trial to eliminate HBV surface antigen expression in patients chronically infected with HBV.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.